Ezetimibe therapy and its influence on oxidative stress and fibrinolytic activity

Southern Medical Journal

Volumn 103, Issue 5, 2010, Pages 428-433

  Turfaner, Nurver ^a   Uzun, Hafize ^a   Balci, Huriye ^a   Ercan, Meltem A ^a   Karter, Yesari H ^a   Caner, Metin ^a   Sipahioglu, Fikret ^a   Genc, Habibe ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Ezetimibe; Fibrinolytic activity; Hyperlipidemia; Oxidative stress

Indexed keywords

8 ISOPROSTANE; ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE 1; CARBONYL DERIVATIVE; EZETIMIBE; GLUCOSE; OXIDIZED LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; TREATMENT DURATION;

ADULT; ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; AZETIDINES; BLOOD GLUCOSE; FEMALE; FIBRINOLYSIS; HUMANS; HYPERLIPIDEMIAS; ISOPROSTANES; LIPIDS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATIVE STRESS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN CARBONYLATION; TISSUE PLASMINOGEN ACTIVATOR;

EID: 77951781368     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3181d83374     Document Type: Article

References (29)

1. Jeu L, Cheng JW. Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor. Clin Ther 2003;25:2352-2387. (Pubitemid 37267246)
2. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular diseases. J Intern Med 1990;227:273-278. (Pubitemid 20105760)
3. Landin K, Stigendal L, Eriksson E, et al. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 1990;39:1044-1048. (Pubitemid 20351262)
4. Juhan-Vague I, Alessi MC, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med 1996;28:371-380. (Pubitemid 26268257)
5. Schneider DJ, Absher PM, Neimane D, et al. Fibrinolysis and atherogenesis in the JCR: LA-cp rat in relation to insulin and triglyceride concentrations in blood. Diabetologia 1998;41:141-147. (Pubitemid 28088389)
6. Berlett BS, Stadtman ER. Protein oxidation in aging, disease, and oxidative stress. J Biol Chem 1997;272:20313-20316. (Pubitemid 27355575)
7. Stadtman ER. Role of oxidant species in aging. Curr Med Chem 2004; 11:1105-1112.
8. Basarici I, Altekin RE, Demir I, et al. Associations of isoprostanes-related oxidative stress with surrogate subclinical indices and angio-graphic measures of atherosclerosis. Coron Artery Dis 2007;18:615-620. (Pubitemid 351339514)
9. Cakatay U, Kayali R, Uzun H. Relation of plasma protein oxidation parameters and paraoxonase activity in the ageing population. Clin Exp Med 2008;8:51-57. (Pubitemid 351666852)
10. Fuhrman B, Koren L, Volkova N, et al. Atorvastatin therapy in hyper-cholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes. Atherosclerosis 2002;164:179-185. (Pubitemid 34765651)
11. Paragh G, Törocsik D, Seres I, et al. Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia. Curr Med Res Opin 2004;20:1321-1327. (Pubitemid 39120797)
12. Tomás M, Sentí M, García-Faria F, et al. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2000;20:2113-2119.
13. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001;37:1053-1059. (Pubitemid 32304003)
14. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15.
15. Sawamura T, Kume N, Aoyama T, et al. An endothelial receptor for oxidized low-density lipoprotein. Nature 1997;386:73-77. (Pubitemid 27130922)
16. Kosoglou T, Statkevich P, Johnson-Levonas AO, et al. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005;44:467-494. (Pubitemid 40733733)
17. Davidson MH, Ballantyne CM, Kerzner B, et al; Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract 2004;58:746-755. (Pubitemid 39232318)
18. Davis HR Jr, Pula KK, Alton KB, et al. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs. Metabolism 2001;50:1234-1241.
19. Masuda D, Nakagawa-Toyama Y, Nakatani K, et al. Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. Eur J Clin Invest 2009;39:689-698.
20. Bays HE, Ose L, Fraser N, et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 2004;26:1758-1773. (Pubitemid 40089489)
21. Hasselwander O, Savage DA, McMaster D, et al. Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients. Kidney Int 1999;56:289-298. (Pubitemid 29300547)
22. Bolayirli IM, Aslan M, Balci H, et al. Effects of atorvastatin therapy on hypercholesterolemic rabbits with respect to oxidative stress, nitric oxide pathway and homocysteine. Life Sci 2007;8:121-127. (Pubitemid 46921173)
23. Nakou ES, Filippatos TD, Kiortsis DN, et al. The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opin Pharmacother 2008; 9:3151-3158.
24. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. London, United Kingdom, Oxford University Press, 1999.
25. Martino F, Loffredo L, Carnevale R, et al. Oxidative stress is associated with arterial dysfunction and enhanced intima-media thickness in children with hypercholesterolemia: the potential role of nicotinamide-adenine dinucleotide phosphate oxidase. Pediatrics 2008;12:e648-e55.
26. Shacter E. Quantification and significance of protein oxidation in biological samples. Drug Metab Rev 2000;32:307-326. (Pubitemid 32001909)
27. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998;1643-1650.
28. Koh KK. Effects of HMG-CoA inhibitor on hemostasis. Int J Cardiol 2000;76:23-32.
29. Wiesbauer F, Kaun C, Zorn G, et al. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins. Br J Pharmacol 2002;135:284-292. (Pubitemid 34102123)